Ignyta Stock Price, News & Analysis (NASDAQ:RXDX)

$26.95 0.00 (0.00 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$26.95
Today's Range$26.95 - $26.95
52-Week Range$5.80 - $27.10
Volume254,655 shs
Average Volume3.04 million shs
Market Capitalization$1.79 billion
P/E Ratio-9.94
Dividend YieldN/A
Beta184.87

About Ignyta (NASDAQ:RXDX)

Ignyta logoIgnyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.

Receive RXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for RXDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:RXDX
CUSIPN/A
Phone+1-858-2555959

Debt

Debt-to-Equity Ratio0.34%
Current Ratio6.07%
Quick Ratio6.07%

Price-To-Earnings

Trailing P/E Ratio-9.94464944649446
Forward P/E Ratio-11.87
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.28 per share
Price / Book11.82

Profitability

Trailing EPS($2.71)
Net Income$-103,630,000.00
Net MarginsN/A
Return on Equity-140.88%
Return on Assets-83.79%

Miscellaneous

Employees112
Outstanding Shares67,590,000

Ignyta (NASDAQ:RXDX) Frequently Asked Questions

What is Ignyta's stock symbol?

Ignyta trades on the NASDAQ under the ticker symbol "RXDX."

How were Ignyta's earnings last quarter?

Ignyta Inc (NASDAQ:RXDX) announced its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.54) by $0.03. View Ignyta's Earnings History.

Where is Ignyta's stock going? Where will Ignyta's stock price be in 2018?

5 equities research analysts have issued 12-month price targets for Ignyta's shares. Their predictions range from $20.00 to $31.00. On average, they anticipate Ignyta's stock price to reach $26.40 in the next twelve months. View Analyst Ratings for Ignyta.

What are Wall Street analysts saying about Ignyta stock?

Here are some recent quotes from research analysts about Ignyta stock:

  • 1. Cantor Fitzgerald analysts commented, "The merger was announced on December 22, 2017, and the transaction was completed on February 8, 2018." (2/9/2018)
  • 2. According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (1/17/2018)

Who are some of Ignyta's key competitors?

Who are Ignyta's key executives?

Ignyta's management team includes the folowing people:

  • Jonathan E. Lim M.D., Chairman of the Board, President, Chief Executive Officer, Co-Founder (Age 45)
  • Jacob M. Chacko M.D., Chief Financial Officer (Age 38)
  • Zachary Hornby, Chief Operating Officer (Age 38)
  • Valerie Harding Start Ph.D., Senior Vice President - Chemistry, Manufacturing, and Controls (Age 57)
  • Christian V. Kuhlen M.D. Esq., General Counsel, Secretary (Age 44)
  • William R. McCarthy, Chief Business Officer (Age 45)
  • Pratik S. Multani M.D., Chief Medical Officer (Age 50)
  • James A. Bristol Ph.D., Independent Director (Age 70)
  • Alexander W. Casdin, Independent Director (Age 49)
  • Heinrich Dreismann Ph.D., Independent Director (Age 64)

Who owns Ignyta stock?

Ignyta's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.43%), Eagle Asset Management Inc. (3.34%), Gardner Lewis Asset Management L P (2.74%), Alliancebernstein L.P. (2.58%), Carillon Tower Advisers Inc. (2.32%) and Victory Capital Management Inc. (2.29%). Company insiders that own Ignyta stock include Alexander W Casdin, Jacob Chacko, James A Bristol, James L Freddo and Jonathan E Lim. View Institutional Ownership Trends for Ignyta.

Who sold Ignyta stock? Who is selling Ignyta stock?

Ignyta's stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers Inc. PA, Victory Capital Management Inc., Broadfin Capital LLC, Pier Capital LLC, Millennium Management LLC, Altrinsic Global Advisors LLC, TIAA CREF Investment Management LLC and Sphera Funds Management LTD.. View Insider Buying and Selling for Ignyta.

Who bought Ignyta stock? Who is buying Ignyta stock?

Ignyta's stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Gardner Lewis Asset Management L P, Alliancebernstein L.P., Carillon Tower Advisers Inc., Alpine Associates Management Inc., Sand Grove Capital Management LLP, Gabelli Funds LLC and Halcyon Management Partners LP. Company insiders that have bought Ignyta stock in the last two years include Alexander W Casdin, Jacob Chacko, James A Bristol, James L Freddo and Jonathan E Lim. View Insider Buying and Selling for Ignyta.

How do I buy Ignyta stock?

Shares of Ignyta can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ignyta's stock price today?

One share of Ignyta stock can currently be purchased for approximately $26.95.

How big of a company is Ignyta?

Ignyta has a market capitalization of $1.79 billion. The biopharmaceutical company earns $-103,630,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis. Ignyta employs 112 workers across the globe.

How can I contact Ignyta?

Ignyta's mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company can be reached via phone at +1-858-2555959.


MarketBeat Community Rating for Ignyta (RXDX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about Ignyta and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ignyta (NASDAQ:RXDX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.202.403.003.00
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.40$25.60$25.25$21.00
Price Target Upside: 2.15% downside4.30% downside69.46% upside100.00% upside

Ignyta (NASDAQ:RXDX) Consensus Price Target History

Price Target History for Ignyta (NASDAQ:RXDX)

Ignyta (NASDAQ:RXDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018Cantor FitzgeraldReiterated RatingHold$27.00LowView Rating Details
12/28/2017Jefferies GroupDowngradeBuy -> Hold$27.00LowView Rating Details
12/26/2017SunTrust BanksDowngradeBuy -> Hold$25.00 -> $27.00LowView Rating Details
12/26/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralLowView Rating Details
10/12/2017JPMorgan Chase & Co.Reiterated RatingBuy$18.00 -> $20.00N/AView Rating Details
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$32.00 -> $20.00N/AView Rating Details
7/12/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
5/12/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Ignyta (NASDAQ:RXDX) Earnings History and Estimates Chart

Earnings by Quarter for Ignyta (NASDAQ:RXDX)

Ignyta (NASDAQ RXDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.54)($0.51)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.63)($0.56)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.69)($0.96)ViewN/AView Earnings Details
3/14/2017Q4 2016($0.67)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.67)($0.56)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.65)($0.68)ViewN/AView Earnings Details
5/10/2016Q1($0.68)($0.79)ViewListenView Earnings Details
3/14/2016Q415($0.57)($1.32)ViewN/AView Earnings Details
11/9/2015Q315($0.60)($0.49)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.51)ViewListenView Earnings Details
5/11/2015Q115($0.79)($1.15)ViewListenView Earnings Details
4/14/2015($0.79)($1.05)ViewN/AView Earnings Details
3/17/2015Q414($0.59)($2.18)ViewN/AView Earnings Details
11/7/2014Q314$0.01($0.55)$215.50 millionViewN/AView Earnings Details
8/12/2014($0.26)($0.28)$0.15 millionViewN/AView Earnings Details
5/12/2014($0.37)($0.28)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ignyta (NASDAQ:RXDX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.44)($0.44)($0.44)
Q2 20181($0.45)($0.45)($0.45)
Q3 20181($0.46)($0.46)($0.46)
Q4 20181($0.47)($0.47)($0.47)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Ignyta (NASDAQ:RXDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ignyta (NASDAQ RXDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.08%
Institutional Ownership Percentage: 72.28%
Insider Trades by Quarter for Ignyta (NASDAQ:RXDX)
Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Ignyta (NASDAQ RXDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/15/2016James A BristolDirectorBuy5,000$5.65$28,250.0021,667View SEC Filing  
5/4/2016Alexander W CasdinDirectorBuy232,000$6.25$1,450,000.00100,000View SEC Filing  
3/17/2016Jacob ChackoCFOBuy10,000$5.64$56,400.0042,838View SEC Filing  
3/17/2016James L FreddoDirectorBuy3,000$5.39$16,170.003,000View SEC Filing  
3/17/2016Jonathan E LimCEOBuy24,852$5.51$136,934.5297,000View SEC Filing  
12/16/2015Jacob ChackoCFOBuy1,500$12.00$18,000.006,438View SEC Filing  
8/20/2015City Hill Venture Partners I,major shareholderBuy8,480$12.90$109,392.003,325,148View SEC Filing  
6/15/2015Robert WildVPBuy1,200$16.35$19,620.00View SEC Filing  
3/20/2015Jonathan E LimCEOBuy20,000$9.01$180,200.00View SEC Filing  
3/17/2015Alexander W CasdinDirectorBuy408,750$10.00$4,087,500.00View SEC Filing  
11/24/2014Jacob ChackoCFOBuy1,598$6.46$10,323.08View SEC Filing  
8/19/2014Jacob ChackoCFOBuy1,840$7.53$13,855.20View SEC Filing  
8/15/2014Jonathan E LimCEOBuy5,000$7.60$38,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ignyta (NASDAQ RXDX) News Headlines

Source:
DateHeadline
Ignyta Inc (RXDX) Receives Average Recommendation of "Hold" from BrokeragesIgnyta Inc (RXDX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 14 at 12:00 PM
Bonti Appoints Dr. Jacob Chacko to Board of DirectorsBonti Appoints Dr. Jacob Chacko to Board of Directors
www.bizjournals.com - February 12 at 9:12 AM
Cantor Fitzgerald Analysts Give Ignyta (RXDX) a $27.00 Price TargetCantor Fitzgerald Analysts Give Ignyta (RXDX) a $27.00 Price Target
www.americanbankingnews.com - February 9 at 7:16 PM
Ignyta (RXDX) Lifted to "Hold" at ValuEngineIgnyta (RXDX) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - February 4 at 2:52 PM
 Brokerages Expect Ignyta Inc (RXDX) to Announce -$0.44 EPS Brokerages Expect Ignyta Inc (RXDX) to Announce -$0.44 EPS
www.americanbankingnews.com - February 2 at 7:08 PM
Ignyta Inc (RXDX) Given Consensus Recommendation of "Hold" by BrokeragesIgnyta Inc (RXDX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 20 at 10:06 AM
Ignyta (RXDX) Lowered to "Hold" at Zacks Investment ResearchIgnyta (RXDX) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 17 at 12:42 PM
 Analysts Expect Ignyta Inc (RXDX) Will Announce Earnings of -$0.44 Per Share Analysts Expect Ignyta Inc (RXDX) Will Announce Earnings of -$0.44 Per Share
www.americanbankingnews.com - January 16 at 7:56 PM
ACT NOW: Monteverde & Associates PC Announces An Investigation of Ignyta, Inc. - RXDXACT NOW: Monteverde & Associates PC Announces An Investigation of Ignyta, Inc. - RXDX
finance.yahoo.com - January 16 at 10:45 AM
Short Interest in Ignyta Inc (RXDX) Declines By 48.0%Short Interest in Ignyta Inc (RXDX) Declines By 48.0%
www.americanbankingnews.com - January 13 at 3:48 AM
Ignyta (RXDX) Stock Rating Lowered by Zacks Investment ResearchIgnyta (RXDX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 9 at 11:58 AM
Pre-Market Technical Scan on Biotech Equities -- Ignyta, Pluristem Therapeutics, Ritter Pharma, and Tenax Therapeutics - PR Newswire (press release)Pre-Market Technical Scan on Biotech Equities -- Ignyta, Pluristem Therapeutics, Ritter Pharma, and Tenax Therapeutics - PR Newswire (press release)
www.prnewswire.com - January 8 at 11:00 AM
Ignyta to Present at 36th Annual J.P. Morgan Healthcare ConferenceIgnyta to Present at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:59 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to ShareholdersSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to Shareholders
finance.yahoo.com - January 3 at 3:29 PM
 Analysts Anticipate Ignyta Inc (RXDX) to Post -$0.44 EPS Analysts Anticipate Ignyta Inc (RXDX) to Post -$0.44 EPS
www.americanbankingnews.com - December 31 at 1:30 AM
Ignyta (RXDX) Downgraded by Jefferies Group to "Hold"Ignyta (RXDX) Downgraded by Jefferies Group to "Hold"
www.americanbankingnews.com - December 29 at 3:34 PM
Cantor Fitzgerald Reiterates $23.00 Price Target for Ignyta (RXDX)Cantor Fitzgerald Reiterates $23.00 Price Target for Ignyta (RXDX)
www.americanbankingnews.com - December 29 at 3:34 PM
Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM ... - Business Wire (press release)Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM ... - Business Wire (press release)
www.businesswire.com - December 29 at 3:29 PM
BRIEF-Ignyta To Commence Phase 1 Study For RXDX-106 In Early 2018BRIEF-Ignyta To Commence Phase 1 Study For RXDX-106 In Early 2018
www.reuters.com - December 29 at 10:58 AM
Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) InhibitorIgnyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor
finance.yahoo.com - December 29 at 10:58 AM
Cantor Fitzgerald Downgrades Ignyta, Inc (RXDX) to Neutral Following AcquisitionCantor Fitzgerald Downgrades Ignyta, Inc (RXDX) to Neutral Following Acquisition
www.streetinsider.com - December 28 at 3:04 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to ShareholdersINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to Shareholders
finance.yahoo.com - December 28 at 3:04 PM
Stock Traders Buy High Volume of Put Options on Ignyta (RXDX)Stock Traders Buy High Volume of Put Options on Ignyta (RXDX)
www.americanbankingnews.com - December 28 at 2:38 AM
Ignyta (RXDX) Lowered to Hold at Cantor FitzgeraldIgnyta (RXDX) Lowered to Hold at Cantor Fitzgerald
www.americanbankingnews.com - December 27 at 7:26 PM
Earnings Visibility Make Ignyta (RXDX) a Buy - Investorplace.comEarnings Visibility Make Ignyta (RXDX) a Buy - Investorplace.com
investorplace.com - December 27 at 6:35 PM
Ignyta (RXDX) and Its Peers Critical ContrastIgnyta (RXDX) and Its Peers Critical Contrast
www.americanbankingnews.com - December 26 at 9:21 PM
Analyzing Ignyta (RXDX) & Its CompetitorsAnalyzing Ignyta (RXDX) & Its Competitors
www.americanbankingnews.com - December 26 at 9:21 PM
Earnings Visibility Make Ignyta (RXDX) a BuyEarnings Visibility Make Ignyta (RXDX) a Buy
investorplace.com - December 26 at 11:17 AM
SunTrust Banks Lowers Ignyta (RXDX) to HoldSunTrust Banks Lowers Ignyta (RXDX) to Hold
www.americanbankingnews.com - December 26 at 10:38 AM
Ignyta (RXDX) Lowered to Neutral at Ladenburg Thalmann Financial ServicesIgnyta (RXDX) Lowered to Neutral at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - December 26 at 7:36 AM
WeissLaw LLP Investigates Ignyta Inc. Acquisition - PR Newswire (press release)WeissLaw LLP Investigates Ignyta Inc. Acquisition - PR Newswire (press release)
www.prnewswire.com - December 24 at 3:50 PM
Roche Bolsters Cancer Portfolio With $1.7 Billion Ignyta Deal - Wall Street JournalRoche Bolsters Cancer Portfolio With $1.7 Billion Ignyta Deal - Wall Street Journal
www.wsj.com - December 24 at 3:50 PM
Roche to buy US cancer drugmaker Ignyta for $1.7 billion - ReutersRoche to buy US cancer drugmaker Ignyta for $1.7 billion - Reuters
www.reuters.com - December 24 at 3:50 PM
Could These 2 Biotech Busted IPOs Be the Next Ignyta?Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?
finance.yahoo.com - December 23 at 3:56 PM
Pre-Open Movers 12/22: (RXDX) (LPJC) (SGH) Higher; (AGRX) (DPW) (LTEA) Lower (more...)Pre-Open Movers 12/22: (RXDX) (LPJC) (SGH) Higher; (AGRX) (DPW) (LTEA) Lower (more...)
www.streetinsider.com - December 22 at 3:56 PM
WeissLaw LLP Investigates Ignyta Inc. AcquisitionWeissLaw LLP Investigates Ignyta Inc. Acquisition
finance.yahoo.com - December 22 at 3:56 PM
Roche Buys Cancer Drug Maker Ignyta In A $1.7 Billion DealRoche Buys Cancer Drug Maker Ignyta In A $1.7 Billion Deal
finance.yahoo.com - December 22 at 3:56 PM
Cantor Fitzgerald Analysts Give Ignyta (RXDX) a $23.00 Price TargetCantor Fitzgerald Analysts Give Ignyta (RXDX) a $23.00 Price Target
www.americanbankingnews.com - December 22 at 11:36 AM
Ignyta (RXDX) Lowered to Hold at Jefferies GroupIgnyta (RXDX) Lowered to Hold at Jefferies Group
www.americanbankingnews.com - December 22 at 11:36 AM
Stocks Trade Lower but Remain On Track for Weekly GainsStocks Trade Lower but Remain On Track for Weekly Gains
www.thestreet.com - December 22 at 9:53 AM
Ignyta Inc. (RXDX) Has Leaped To A New High After Bought By RocheIgnyta Inc. (RXDX) Has Leaped To A New High After Bought By Roche
www.nasdaq.com - December 22 at 9:53 AM
Why Ignyta, Inc. Stock Is Soaring TodayWhy Ignyta, Inc. Stock Is Soaring Today
finance.yahoo.com - December 22 at 9:53 AM
Contrasting Ignyta (RXDX) & The CompetitionContrasting Ignyta (RXDX) & The Competition
www.americanbankingnews.com - December 21 at 7:12 PM
Head-To-Head Analysis: Ignyta (RXDX) and Its PeersHead-To-Head Analysis: Ignyta (RXDX) and Its Peers
www.americanbankingnews.com - December 19 at 9:32 AM
 Analysts Expect Ignyta, Inc. (RXDX) to Announce -$0.44 Earnings Per Share Analysts Expect Ignyta, Inc. (RXDX) to Announce -$0.44 Earnings Per Share
www.americanbankingnews.com - December 14 at 1:18 AM
Financial Review: Ignyta (RXDX) vs. Its PeersFinancial Review: Ignyta (RXDX) vs. Its Peers
www.americanbankingnews.com - December 13 at 5:12 AM
Ignyta, Inc. (RXDX) Receives Consensus Recommendation of "Buy" from BrokeragesIgnyta, Inc. (RXDX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 1 at 3:54 PM
Ignyta, Inc. Fundamental Analysis : November 30, 2017Ignyta, Inc. Fundamental Analysis : November 30, 2017
finance.yahoo.com - December 1 at 12:32 PM
Pre-Market Technical Scan on Biotech Equities -- Pluristem Therapeutics, Ritter Pharma, Ignyta, and Tenax TherapeuticsPre-Market Technical Scan on Biotech Equities -- Pluristem Therapeutics, Ritter Pharma, Ignyta, and Tenax Therapeutics
www.bizjournals.com - November 29 at 9:48 AM
Ignyta to Participate at the Global Mizuho Investor ConferenceIgnyta to Participate at the Global Mizuho Investor Conference
finance.yahoo.com - November 29 at 9:48 AM

SEC Filings

Ignyta (NASDAQ:RXDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ignyta (NASDAQ:RXDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ignyta (NASDAQ RXDX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.